To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Phase 3

Completed

• Conditions: Seizure Disorder, Partial

• Registration Number: NCT00141336
• Lead Sponsor: Pfizer

Brief Summary

To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.

Detailed Description

Not available

Study Timeline

• Study Start: 1999-11
• Study Completion: 2005-07
• Study First Submitted: 2005-08-30
• Study First Submitted QC: 2005-08-30
• Study First Posted: 2005-09-01
• Status Verified: 2006-12
• Last Update Submitted: 2006-12-28
• Last Update Posted: 2007-01-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

• Must have met the inclusion criteria for preceding double-blind study
• Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria

• Cannot have absence seizures

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety Tolerability

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇨🇦 Toronto, Ontario, Canada